ArticleJournal of nucleic acids2013
Mesenchymal stem cell therapy in diabetes mellitus: progress and challenges.
Article in Journal of nucleic acids, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pooled it
- Diabetic microenvironment deteriorates the regenerative capacities of adipose mesenchymal stromal cells.Diabetology & metabolic syndrome · 2024Article
- Human mesenchymal stem cells exhibit altered mitochondrial dynamics and poor survival in high glucose microenvironment.World journal of stem cells · 2023Article
- Article
- Antidiabetic Effects of Bisamide Derivative of Dicarboxylic Acid in Metabolic Disorders.International journal of molecular sciences · 2020Article
- Impact of Diabetes Mellitus on Human Mesenchymal Stromal Cell Biology and Functionality: Implications for Autologous Transplantation.Stem cell reviews and reports · 2019Review
- Endothelial Progenitor Cells as Pathogenetic and Diagnostic Factors, and Potential Targets for GLP-1 in Combination with Metabolic Syndrome and Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2019Article
- Cdc42 Promotes ADSC-Derived IPC Induction, Proliferation, And Insulin Secretion Via Wnt/β-Catenin Signaling.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?Frontiers in immunology · 2019Review
- Phenolic compounds apigenin, hesperidin and kaempferol reduce in vitro lipid accumulation in human adipocytes.Journal of translational medicine · 2017Article
- Lipopolysaccharide treatment induces genome-wide pre-mRNA splicing pattern changes in mouse bone marrow stromal stem cells.BMC genomics · 2016Article
- Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus.World journal of stem cells · 2016Article
- Mesenchymal Stem Cells and Metabolic Syndrome: Current Understanding and Potential Clinical Implications.Stem cells international · 2016Review
- Theoretical and Practical Issues That Are Relevant When Scaling Up hMSC Microcarrier Production Processes.Stem cells international · 2016Article
- CdSe/ZnS Quantum Dots-Labeled Mesenchymal Stem Cells for Targeted Fluorescence Imaging of Pancreas Tissues and Therapy of Type 1 Diabetic Rats.Nanoscale research letters · 2015Article
- Mesenchymal Stem Cells: Rising Concerns over Their Application in Treatment of Type One Diabetes Mellitus.Journal of diabetes research · 2015Review
- Mesenchymal stem cells: Potential role in corneal wound repair and transplantation.World journal of stem cells · 2014Review
- Stem cell therapy for the treatment of parasitic infections: is it far away?Parasitology research · 2014Article
- A modified method of insulin producing cells' generation from bone marrow-derived mesenchymal stem cells.Journal of diabetes research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced type 2 diabetes mellitus is associated with significant morbidity and mortality due to cardiovascular, nervous, and renal complications. Attempts to cure diabetes mellitus using islet transplantation have been successful in providing a source for insulin secreting cells. However, limited donors, graft rejection, the need for continued immune suppression, and exhaustion of the donor cell pool prompted the search for a more sustained source of insulin secreting cells. Stem cell therapy is a promising alternative for islet transplantation in type 2 diabetic patients who fail to control hyperglycemia even with insulin injection. Autologous stem cell transplantation may provide the best outcome for those patients, since autologous cells are readily available and do not entail prolonged hospital stays or sustained immunotoxic therapy. Among autologous adult stem cells, mesenchymal stem cells (MSCs) therapy has been applied with varying degrees of success in both animal models and in clinical trials. This review will focus on the advantages of MSCs over other types of stem cells and the possible mechanisms by which MSCs transplant restores normoglycemia in type 2 diabetic patients. Sources of MSCs including autologous cells from diabetic patients and the use of various differentiation protocols in relation to best transplant outcome will be discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.